Trial site
Fakultna nemocnica s poliklinikou Zilina
Žilina, 012 07, SlovakiaEU-13 widening countryNot linked to an institution yet
- 9running trials
- 12closed trials
The trials here
What the 21 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 25 trials
- Phase 2/33 trials
- Phase 41 trial
- Status
- Completed12 trials
- Active, not recruiting4 trials
- Recruiting4 trials
- Not yet recruiting1 trial
- Lead sponsor
- Bayer2 trials
- Eyebiotech Limited2 trials
- Pfizer2 trials
- AbbVie1 trial
- Alexion Pharmaceuticals Inc.1 trial
- and 13 more
Running trials
Recruiting
A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)
2025-524894-17-00· Phase 2/3· Eyebiotech Limited· Source
Recruiting
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
NCT07614776· Phase 3· Amgen· Source
Recruiting
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065· Phase 3· AbbVie· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Recruiting
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839· Phase 2· Boehringer Ingelheim· Source
Active, not recruiting
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080· Phase 2/3· EyeBiotech Ltd.· Source
Active, not recruiting
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)
2024-510944-30-00· Phase 2/3· Eyebiotech Limited· Source
Active, not recruiting
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022· Phase 2· Astellas Pharma Global Development, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC.
NCT06280196· Phase 3· Bio-Thera Solutions Ltd.· Source
Completed
A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
NCT06591598· Phase 4· Bayer· Source
Completed
A Clinical Trial to compare Efficacy, Safety, Tolerability of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration
2023-509206-29-00· Phase 3· Rophibio Inc.· Source
Active, not recruiting
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632· Phase 2· Pfizer· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
NCT05369052· Phase 3· MicuRx· Source
Completed
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT05019521· Phase 2· Alexion Pharmaceuticals Inc.· Source
Completed
A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneration
NCT04757636· Phase 3· Opthea Limited· Source
Completed
A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
NCT04740671· Phase 3· Shanghai Henlius Biotech· Source
Completed
Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD
NCT04690556· Phase 3· Lupin Ltd.· Source
Completed
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
NCT04423718· Phase 3· Bayer· Source
Completed
A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema
NCT04527107· Phase 2· Oxurion· Source
Report an error